These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25809858)

  • 1. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
    Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Fujiwara Y; Tamura Y; Wakui H; Honda K; Mizugaki H; Kitazono S; Tanabe Y; Asahina H; Yamazaki N; Suzuki S; Matsuoka M; Ogita Y; Tamura T
    Invest New Drugs; 2015 Jun; 33(3):641-51. PubMed ID: 25809858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
    Leijen S; Middleton MR; Tresca P; Kraeber-Bodéré F; Dieras V; Scheulen ME; Gupta A; Lopez-Valverde V; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Schellens JH; Eberhardt WE
    Clin Cancer Res; 2012 Sep; 18(17):4794-805. PubMed ID: 22767668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
    Honda K; Yamamoto N; Nokihara H; Tamura Y; Asahina H; Yamada Y; Suzuki S; Yamazaki N; Ogita Y; Tamura T
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):577-84. PubMed ID: 23860959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
    Zimmer L; Barlesi F; Martinez-Garcia M; Dieras V; Schellens JH; Spano JP; Middleton MR; Calvo E; Paz-Ares L; Larkin J; Pacey S; Venturi M; Kraeber-Bodéré F; Tessier JJ; Eberhardt WE; Paques M; Guarin E; Meresse V; Soria JC
    Clin Cancer Res; 2014 Aug; 20(16):4251-61. PubMed ID: 24947927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.
    Kraeber-Bodéré F; Carlier T; Naegelen VM; Shochat E; Lumbroso J; Trampal C; Nagarajah J; Chua S; Hugonnet F; Stokkel M; Gleeson F; Tessier J
    J Nucl Med; 2012 Dec; 53(12):1836-46. PubMed ID: 23143089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
    Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
    Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.
    Saka H; Kitagawa C; Kogure Y; Takahashi Y; Fujikawa K; Sagawa T; Iwasa S; Takahashi N; Fukao T; Tchinou C; Landers D; Yamada Y
    Invest New Drugs; 2017 Aug; 35(4):451-462. PubMed ID: 28070720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
    Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
    J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
    Goldman JW; Rosen LS; Tolcher AW; Papadopoulos K; Beeram M; Shi P; Pitou C; Bell R; Kulanthaivel P; Zhang X; Fink A; Chan EM; Shahir A; Farrington D; Patnaik A
    Invest New Drugs; 2018 Aug; 36(4):629-637. PubMed ID: 29196957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
    Lorusso PM; Adjei AA; Varterasian M; Gadgeel S; Reid J; Mitchell DY; Hanson L; DeLuca P; Bruzek L; Piens J; Asbury P; Van Becelaere K; Herrera R; Sebolt-Leopold J; Meyer MB
    J Clin Oncol; 2005 Aug; 23(23):5281-93. PubMed ID: 16009947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
    Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
    Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
    Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
    Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
    Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
    Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
    Shimizu T; Fukuoka K; Takeda M; Iwasa T; Yoshida T; Horobin J; Keegan M; Vaickus L; Chavan A; Padval M; Nakagawa K
    Cancer Chemother Pharmacol; 2016 May; 77(5):997-1003. PubMed ID: 27025608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.
    Adjei AA; LoRusso P; Ribas A; Sosman JA; Pavlick A; Dy GK; Zhou X; Gangolli E; Kneissl M; Faucette S; Neuwirth R; Bózon V
    Invest New Drugs; 2017 Feb; 35(1):47-58. PubMed ID: 27650277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.
    LoRusso PM; Krishnamurthi SS; Rinehart JJ; Nabell LM; Malburg L; Chapman PB; DePrimo SE; Bentivegna S; Wilner KD; Tan W; Ricart AD
    Clin Cancer Res; 2010 Mar; 16(6):1924-37. PubMed ID: 20215549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
    Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
    Delord JP; Italiano A; Awada A; Aftimos P; Houédé N; Lebbé C; Pages C; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Faivre S; Gomez-Roca C; Scheuler A; Massimini G; Raymond E
    Target Oncol; 2021 Jan; 16(1):37-46. PubMed ID: 33170484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
    Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
    Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.
    Esaki T; Hirai F; Makiyama A; Seto T; Bando H; Naito Y; Yoh K; Ishihara K; Kakizume T; Natsume K; Myers A; Doi T
    Cancer Sci; 2019 Apr; 110(4):1340-1351. PubMed ID: 30724423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.